Source comparison
Safety Profile: Tesamorelin vs CJC-1295 Ipamorelin Adverse Events
The safety profiles for tesamorelin vs CJC-1295 Ipamorelin differ primarily in available data volume and study population breadth. Tesamorelin’s Phase III trials provide the most comprehensive adverse event dataset for any GHRH peptide. Common adverse events i
This comparison does not assign a generated winner or score.
- The safety profiles for tesamorelin vs CJC-1295 Ipamorelin differ primarily in available data volume and study population breadth. Tesamorelin’s Phase III trials provide the most comprehensive adverse event dataset for any GHRH peptide. Common adverse events in the pivotal trials included injection site reactions (25.7% tesamorelin vs 12.6% placebo), fluid retention (8.4%), arthralgia (7.6%), and extremity pain (4.5%). No significant glucose metabolism changes were observed at 26 weeks.
- A 52-week extension study confirmed the adverse event profile remained consistent with no new safety signals — a favorable finding that distinguishes the tesamorelin safety database in the tesamorelin vs CJC-1295 Ipamorelin literature.
- For CJC-1295, Phase II adverse events included transient dose-dependent flushing, water retention at higher doses, and mild injection site reactions. No serious adverse events were attributed to CJC-1295 in published trials at research doses. Ipamorelin’s selective GHRP profile produces fewer off-target effects than GHRP-6 or GHRP-2 — Phase I data showed less than 10% cortisol or prolactin change at effective GH-stimulating doses, making it the preferred GHRP in current tesamorelin vs CJC-1295 Ipamorelin research designs. For full adverse event context, review the peptide side effects overview and the tesamorelin Phase III safety data on PubMed.